Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study
Open Access
- 1 February 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (3) , 1560-1566
- https://doi.org/10.1182/blood-2007-07-100958
Abstract
To study prognostic factors of progression/relapse, data concerning 225 children enrolled between 1987 and 1997 in Berlin-Frankfurt-Münster, Société Française d'Oncologie Pédiatrique and United Kingdom Children's Cancer Study Group prospective studies for the treatment of anaplastic large cell lymphoma (ALCL) were merged. Median follow-up was 9.3 years. Five-year overall survival and event-free survival of the whole population was 81% (95% confidence interval, 76%-86%) and 69% (63%-74%), respectively. B symptoms, mediastinal involvement, skin lesions, visceral involvement, St Jude stage 3-4, Ann Arbor stage 3-4, and elevated lactate dehydrogenase increased the risk of progression/relapse in the univariate analysis. In the multivariate analysis, 3 factors remained significant: mediastinal involvement (relative risk [RR] = 2.1 [1.2-3.5]), visceral involvement defined as lung, liver, or spleen involvement (RR = 2.1 [1.3-3.6]), and skin lesions (RR = 1.9 [1.1-3.2]). Five-year progression-free survival (PFS) of the 81 patients with none of these risk factors was 89% [82%-96%], contrasting with a 5-year PFS of 61% [53%-69%] in the 144 patients with at least 1 risk factor (RR = 4.4 [2.2-8.9; P < .001). In conclusion, 3 factors associated with an increased risk of failure in childhood ALCL have been defined: mediastinal involvement, visceral involvement, and skin lesions.Keywords
This publication has 27 references indexed in Scilit:
- Anaplastic large cell lymphoma of bone—is it a bad tumor?Pediatric Blood & Cancer, 2007
- Anaplastic large cell lymphoma treated with a leukemia‐like therapyCancer, 2005
- Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III TrialJournal of Clinical Oncology, 2005
- Assessment of t(2;5)(p23;q35) Translocation and Variants in Pediatric ALK+ Anaplastic Large Cell LymphomaAmerican Journal of Clinical Pathology, 2004
- Assessment of t(2;5)(p23;q35) Translocation and Variants in Pediatric ALK+ Anaplastic Large Cell LymphomaAmerican Journal of Clinical Pathology, 2004
- Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL)Medical and Pediatric Oncology, 2001
- Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90Blood, 2001
- Anaplastic large cell lymphoma (Ki‐1+/CD30+) in childhoodMedical and Pediatric Oncology, 1993
- Adult Ki-1-Positive Large Cell Anaplastic Lymphoma Presenting with Skin LesionsActa Haematologica, 1989
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978